MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the p...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2016-10-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/2643 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850088438314827776 |
|---|---|
| author | Maria Ilaria Del Principe |
| author_facet | Maria Ilaria Del Principe |
| author_sort | Maria Ilaria Del Principe |
| collection | DOAJ |
| description | Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients’ risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help identifying patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry (MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management. |
| format | Article |
| id | doaj-art-a73aa35d7d024dfa92b5aa1f36342d63 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2016-10-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-a73aa35d7d024dfa92b5aa1f36342d632025-08-20T02:43:00ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062016-10-0180e2016052e201605210.4084/mjhid.2016.0521643MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.Maria Ilaria Del Principe01Ematologia, Dipartimento di Biomedicina e Prevenzione Università degli Studi di Roma "Tor Vergata", Roma, Italia.Pretreatment assessment of cytogenetic/genetic signature of acute myeloid leukemia (AML) has been consistently shown to play a major prognostic role but also to fail at predicting outcome on individual basis, even in low-risk AML. Therefore, we are in need of further accurate methods to refine the patients’ risk allocation process, distinguishing more adequately those who are likely to recur from those who are not. In this view, there is now evidence that the submicroscopic amounts of leukemic cells (called minimal residual disease, MRD), measured during the course of treatment, indicate the quality of response to therapy. Therefore, MRD might serve as an independent, additional biomarker to help identifying patients at higher risk of relapse. Detection of MRD requires the use of highly sensitive ancillary techniques, such as polymerase chain reaction (PCR) and multiparametric flow cytometry (MPFC). In the present manuscript, we will review the current approaches to investigate MRD and its clinical applications in AML management.http://www.mjhid.org/index.php/mjhid/article/view/2643acute myeloid leukemia, minimal residual disease, flow cytometry, PCR, prognosis |
| spellingShingle | Maria Ilaria Del Principe MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. Mediterranean Journal of Hematology and Infectious Diseases acute myeloid leukemia, minimal residual disease, flow cytometry, PCR, prognosis |
| title | MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. |
| title_full | MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. |
| title_fullStr | MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. |
| title_full_unstemmed | MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. |
| title_short | MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS. |
| title_sort | minimal residual disease in acute myeloid leukemia of adults determination prognostic impact and clinical applications |
| topic | acute myeloid leukemia, minimal residual disease, flow cytometry, PCR, prognosis |
| url | http://www.mjhid.org/index.php/mjhid/article/view/2643 |
| work_keys_str_mv | AT mariailariadelprincipe minimalresidualdiseaseinacutemyeloidleukemiaofadultsdeterminationprognosticimpactandclinicalapplications |